Summary
Vertex Pharmaceuticals reported strong revenue growth in 2019, driven primarily by its suite of cystic fibrosis (CF) treatments, particularly the newly approved TRIKAFTA. The company's strategic focus remains on advancing its CF pipeline and expanding treatment options for patients, aiming to cover up to 90% of the CF population. Beyond CF, Vertex is actively investing in and diversifying its pipeline with promising early-stage programs in areas such as alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, pain, sickle cell disease, beta-thalassemia, type 1 diabetes, and muscular dystrophies. Financially, Vertex demonstrated robust performance with increasing product revenues and controlled expense growth, leading to significant operating margins. The company also made substantial strategic investments in 2019 through acquisitions, notably Semma Therapeutics for type 1 diabetes and Exonics for genetic therapies. With a strong cash position and clear revenue drivers in its CF franchise, Vertex is well-positioned for continued growth and pipeline advancement.
Financial Highlights
53 data points| Revenue | $4.16B |
| Cost of Revenue | $547.80M |
| Gross Profit | $3.62B |
| R&D Expenses | $1.75B |
| SG&A Expenses | $658.50M |
| Operating Expenses | $2.97B |
| Operating Income | $1.20B |
| Interest Expense | $58.50M |
| Net Income | $1.18B |
| EPS (Basic) | $4.58 |
| EPS (Diluted) | $4.51 |
| Shares Outstanding (Basic) | 256.70M |
| Shares Outstanding (Diluted) | 260.70M |
Key Highlights
- 1Strong revenue growth in 2019, driven by a significant increase in product revenues, largely from existing and newly approved cystic fibrosis (CF) medicines.
- 2FDA approval of TRIKAFTA in October 2019 for CF patients aged 12 and older with at least one F508del mutation, expanding treatment eligibility and addressing a key unmet need.
- 3Active pipeline expansion beyond CF, with notable progress in early-stage programs for alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, pain, and gene/cell therapies for sickle cell disease, beta-thalassemia, type 1 diabetes, and muscular dystrophies.
- 4Significant strategic acquisitions in 2019, including Semma Therapeutics ($950 million) for type 1 diabetes cell therapies and Exonics ($245 million upfront) for genetic therapies for neuromuscular diseases, bolstering the company's diversification strategy.
- 5Robust financial health demonstrated by substantial cash reserves ($3.8 billion as of December 31, 2019) and increasing operating income, reflecting successful commercialization and efficient operations.
- 6Continued focus on obtaining ex-U.S. regulatory approvals and reimbursement for key products, including the submission of a Marketing Authorization Application for TRIKAFTA to the EMA.
- 7Management expressed confidence in continued revenue growth in 2020, supported by TRIKAFTA's launch, label expansions, and broader market access for its CF portfolio.